$CARA
Cara Therapeutics, Inc.

2015 Q4 Form 10-Q Financial Statement

#000119312515372144 Filed on November 09, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $2.440M $1.125M
YoY Change -100.0% 116.89% 10.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.200M $1.900M $1.500M
YoY Change 22.22% 26.67% 87.5%
% of Gross Profit
Research & Development $7.600M $5.584M $6.208M
YoY Change 117.14% -10.05% 64.93%
% of Gross Profit
Depreciation & Amortization $260.0K $190.0K $200.0K
YoY Change 36.84% -5.0% 5.26%
% of Gross Profit
Operating Expenses $9.700M $7.449M $7.728M
YoY Change 83.02% -3.61% 69.51%
Operating Profit -$5.009M -$6.603M
YoY Change -24.14% 86.47%
Interest Expense $100.0K $22.00K $26.00K
YoY Change -15.38% -102.51%
% of Operating Profit
Other Income/Expense, Net $22.00K
YoY Change
Pretax Income -$9.700M -$4.987M -$6.577M
YoY Change 125.58% -24.18% 43.76%
Income Tax -$100.0K -$200.0K -$32.00K
% Of Pretax Income
Net Earnings -$9.530M -$4.787M -$6.545M
YoY Change 128.43% -26.86% 43.06%
Net Earnings / Revenue -196.19% -581.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$348.0K -$188.2K -$286.3K
COMMON SHARES
Basic Shares Outstanding 27.23M shares 25.55M shares 22.71M shares
Diluted Shares Outstanding 25.55M shares 22.71M shares

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.7M $111.1M $58.40M
YoY Change 102.47% 90.24% 229.94%
Cash & Equivalents $15.10M $111.1M $58.39M
Short-Term Investments $91.60M
Other Short-Term Assets $1.700M $2.000M $900.0K
YoY Change 466.67% 122.22% 50.0%
Inventory
Prepaid Expenses $1.729M $1.971M $928.0K
Receivables
Other Receivables
Total Short-Term Assets $108.9M $115.7M $59.41M
YoY Change 104.96% 94.71% 224.64%
LONG-TERM ASSETS
Property, Plant & Equipment $1.263M $1.517M $2.262M
YoY Change -39.4% -32.94% -24.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $700.0K $700.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.963M $2.217M $2.962M
YoY Change -29.49% -25.15% -22.05%
TOTAL ASSETS
Total Short-Term Assets $108.9M $115.7M $59.41M
Total Long-Term Assets $1.963M $2.217M $2.962M
Total Assets $110.9M $117.9M $62.37M
YoY Change 98.26% 89.02% 182.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.965M $1.263M $1.715M
YoY Change 281.55% -26.36% 31.92%
Accrued Expenses $3.300M $2.100M $2.400M
YoY Change 135.71% -12.5% 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.268M $3.374M $6.093M
YoY Change 55.03% -44.62% -16.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $700.0K $900.0K
YoY Change -33.33% -22.22% -25.0%
Total Long-Term Liabilities $600.0K $700.0K $900.0K
YoY Change -33.33% -22.22% -25.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.268M $3.374M $6.093M
Total Long-Term Liabilities $600.0K $700.0K $900.0K
Total Liabilities $5.900M $4.000M $7.000M
YoY Change 37.21% -42.86% -17.65%
SHAREHOLDERS EQUITY
Retained Earnings -$104.9M -$95.36M -$76.03M
YoY Change 30.79% 25.43%
Common Stock $210.0M $209.2M $23.00K
YoY Change 59.23% 909569.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $105.0M $113.9M $55.34M
YoY Change
Total Liabilities & Shareholders Equity $110.9M $117.9M $62.40M
YoY Change 98.26% 88.94% 182.35%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$9.530M -$4.787M -$6.545M
YoY Change 128.43% -26.86% 43.06%
Depreciation, Depletion And Amortization $260.0K $190.0K $200.0K
YoY Change 36.84% -5.0% 5.26%
Cash From Operating Activities -$4.170M -$7.810M -$4.490M
YoY Change -28.35% 73.94% 30.52%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 -$20.00K
YoY Change 0.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$91.66M
YoY Change
Cash From Investing Activities -$91.67M $0.00 -$20.00K
YoY Change 916600.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $75.23M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -190.0K 75.74M 90.00K
YoY Change -272.73% 84055.56%
NET CHANGE
Cash From Operating Activities -4.170M -7.810M -4.490M
Cash From Investing Activities -91.67M 0.000 -20.00K
Cash From Financing Activities -190.0K 75.74M 90.00K
Net Change In Cash -96.03M 67.93M -4.420M
YoY Change 1578.85% -1636.88% 28.49%
FREE CASH FLOW
Cash From Operating Activities -$4.170M -$7.810M -$4.490M
Capital Expenditures -$10.00K $0.00 -$20.00K
Free Cash Flow -$4.160M -$7.810M -$4.470M
YoY Change -28.4% 74.72% 29.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
18.60
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27231583 shares
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
55335000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58393000
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27231583 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27231583 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
913000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
209197000
CY2015Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
708000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
86000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1879000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
113863000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
226000
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
348000
CY2015Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3374000
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
660000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1263000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95361000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117897000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
27000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3374000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
740000
CY2015Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
450000
CY2015Q3 us-gaap Assets
Assets
117897000
CY2015Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
700000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1517000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
115680000
CY2015Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
50000
CY2015Q3 us-gaap Prepaid Insurance
PrepaidInsurance
294000
CY2015Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1971000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111116000
CY2015Q3 us-gaap Other Receivables
OtherReceivables
2143000
CY2015Q3 cara Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1627000
CY2015Q3 cara Accrued Research Projects
AccruedResearchProjects
969000
CY2015Q3 cara Amount Due From Upfront And Milestone Payments With License Agreements
AmountDueFromUpfrontAndMilestonePaymentsWithLicenseAgreements
2100000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-54075000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12357000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22802039 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22802039 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
131840000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
504000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
51662000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
266000
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1946000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
874000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1452000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
515000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80201000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55934000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3398000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
200000
CY2014Q4 us-gaap Assets
Assets
55934000
CY2014Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
700000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2084000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
53150000
CY2014Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18000
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
92000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
287000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52663000
CY2014Q4 cara Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
177000
CY2014Q4 cara Accrued Research Projects
AccruedResearchProjects
549000
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75231000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11818000
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.710 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20351005 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20351005 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0180 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0272 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.650 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20351005 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
us-gaap Net Income Loss
NetIncomeLoss
-13573000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
119000
us-gaap Revenues
Revenues
2263000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
104000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
65586000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1031000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
28000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13736000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-240000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13632000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-59000
us-gaap Share Based Compensation
ShareBasedCompensation
1031000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
1031000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1531000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
46036000
us-gaap Operating Expenses
OperatingExpenses
15999000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-27000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57881000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11609000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1647000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
119000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4390000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
65586000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
57762000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
590000
cara Collaborative Revenue
CollaborativeRevenue
1802000
cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
194000
cara Clinical Compound Revenue
ClinicalCompoundRevenue
159000
cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
302000
cara Non Cash Or Part Non Cash Prepaid Initial Public Offering Costs Offset Against Proceeds Of Initial Public Offering
NonCashOrPartNonCashPrepaidInitialPublicOfferingCostsOffsetAgainstProceedsOfInitialPublicOffering
1465000
cara Noncash Or Part Noncash Unpaid Initial Public Offering And Follow On Public Offering Issuance Costs
NoncashOrPartNoncashUnpaidInitialPublicOfferingAndFollowOnPublicOfferingIssuanceCosts
50000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Business</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Cara Therapeutics, Inc. (the &#x201C;Company&#x201D;, &#x201C;we&#x201D;, &#x201C;our&#x201D; or &#x201C;us&#x201D;) is a clinical-stage biopharmaceutical corporation formed on July&#xA0;2, 2004. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The Company&#x2019;s primary activities to date have been organizing and staffing the company, developing its product candidates, including conducting preclinical studies and clinical trials of CR845-based product candidates and raising capital.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As of September&#xA0;30, 2015, the Company has raised aggregate net proceeds of approximately $204,800 from several rounds of equity financing, including its follow-on offering, which closed in August 2015 (see Note 5 of Notes to Condensed Financial Statements), and the issuance of debt. In addition, the Company earned approximately $32,500 (of which approximately $2,100 was due to the Company as of September&#xA0;30, 2015 and received in October 2015) under its license agreements for CR845, primarily with Maruishi Pharmaceutical Co. Ltd. (&#x201C;Maruishi&#x201D;) and Chong Kun Dang Pharmaceutical Corp. (&#x201C;CKD&#x201D;), and for an earlier product candidate for which development efforts ceased in 2007.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In connection with the license of rights to CR845 in Japan to Maruishi and as part of the earnings described above, in April 2013, the Company received an upfront payment of $15,000, and in August 2014 and September 2015, the Company received an additional $480 and was due an additional $1,725 (net of contractual foreign currency exchange adjustments), respectively, in milestone payments. In connection with the license of rights to CR845 in South Korea to CKD and as part of the earnings described above, in 2012, the Company received aggregate upfront and milestone payments of $1,190, and in August 2015 and September 2015, the Company received an additional $209 and was due an additional $417 (net of South Korean withholding taxes), respectively, in milestone payments.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception. As of September&#xA0;30, 2015, the Company had unrestricted cash and cash equivalents of $111,116 and an accumulated deficit of $95,361. The Company had net cash used in operating activities of $17,310 and $11,818 for the nine months ended September&#xA0;30, 2015 and 2014, respectively. The Company expects that cash and cash equivalents at September&#xA0;30, 2015 will be sufficient to fund its operations beyond one year. The Company recognized net losses of $4,787 and $15,160 for the three and nine months ended September&#xA0;30, 2015, respectively, and $6,545 and $13,573 for the three and nine months ended September&#xA0;30, 2014, respectively, and expects to incur additional net losses and negative cash flows for the full year ending December&#xA0;31, 2015 and for the foreseeable future.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company is subject to risks common to other life science companies including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability protection of proprietary technology, ability to raise additional financing, and compliance with U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.</p> </div>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17310000
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001346830
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2004-07-02
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.671 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
Cara Therapeutics, Inc.
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23737443 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <i>Reclassifications</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain revenue amounting to $159 within the Statements of Operations for the nine months ended September&#xA0;30, 2014 has been reclassified from Collaborative revenue to Clinical compound revenue to conform to the current year presentation.</p> </div>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23737443 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0143 pure
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0189 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> <i>Use of Estimates</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company&#x2019;s estimates and assumptions. Significant estimates include useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front and milestone payments, the determination of prepaid research and development clinical costs and accrued research projects, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.</p> </div>
dei Trading Symbol
TradingSymbol
CARA
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.640 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23737443 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Net Income Loss
NetIncomeLoss
-15160000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
323000
us-gaap Revenues
Revenues
3803000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
49000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1807000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
250000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15459000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1649000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2143000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15410000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-250000
us-gaap Share Based Compensation
ShareBasedCompensation
1807000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
1807000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1452000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
58453000
us-gaap Operating Expenses
OperatingExpenses
19262000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-13000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75776000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13653000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1171000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
323000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5609000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
580000
cara Collaborative Revenue
CollaborativeRevenue
2093000
cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
214000
cara Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
75453000
cara Percentage Of Research And Development Tax Credits Exchanged For Cash
PercentageOfResearchAndDevelopmentTaxCreditsExchangedForCash
0.65 pure
cara Clinical Compound Revenue
ClinicalCompoundRevenue
0
cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
1710000
cara Aggregate Net Proceeds From Equity Financing And Issuance Of Debt
AggregateNetProceedsFromEquityFinancingAndIssuanceOfDebt
204800000
cara Noncash Or Part Noncash Unpaid Initial Public Offering And Follow On Public Offering Issuance Costs
NoncashOrPartNoncashUnpaidInitialPublicOfferingAndFollowOnPublicOfferingIssuanceCosts
222000
cara Upfront And Milestone Payments Earned In Connection With License Agreements
UpfrontAndMilestonePaymentsEarnedInConnectionWithLicenseAgreements
32500000
CY2014Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0192 pure
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.650 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22713040 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22713040 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22713040 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6545000
CY2014Q3 us-gaap Revenues
Revenues
1125000
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
26000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6603000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6577000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-32000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
222000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
7728000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6208000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1520000
CY2014Q3 cara Collaborative Revenue
CollaborativeRevenue
1125000
CY2015Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0177 pure
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2015Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.641 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25545164 shares
CY2015Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25545164 shares
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25545164 shares
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-4787000
CY2015Q3 us-gaap Revenues
Revenues
2440000
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
22000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5009000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4987000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
661000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
7449000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5584000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1865000
CY2015Q3 cara Collaborative Revenue
CollaborativeRevenue
730000
CY2015Q3 cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
1710000

Files In Submission

Name View Source Status
0001193125-15-372144-index-headers.html Edgar Link pending
0001193125-15-372144-index.html Edgar Link pending
0001193125-15-372144.txt Edgar Link pending
0001193125-15-372144-xbrl.zip Edgar Link pending
cara-20150930.xml Edgar Link completed
cara-20150930.xsd Edgar Link pending
cara-20150930_cal.xml Edgar Link unprocessable
cara-20150930_def.xml Edgar Link unprocessable
cara-20150930_lab.xml Edgar Link unprocessable
cara-20150930_pre.xml Edgar Link unprocessable
d97716d10q.htm Edgar Link pending
d97716dex311.htm Edgar Link pending
d97716dex312.htm Edgar Link pending
d97716dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending